BioScrip Inc (NASDAQ:BIOS), on May 8, 2014 announced 2014 first quarter financial results. First quarter revenue from continuing operations was $239.6 million and the net loss from continuing operations was $25.4 million, or $0.37 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.13.BioScrip Inc (NASDAQ:BIOS) stock performance was 17.08% in last session and finished the day at $ 7.13. Traded volume was 4,747,417 shares in the last session and the average volume of the stock remained 1.79 million shares. The beta of the stock remained 0.63. BioScrip Inc (NASDAQ:BIOS) insider ownership is 27.35%.
NPS Pharmaceuticals (NASDAQ:NPSP) had its outperform rating reissued by analysts at Leerink Swann. They currently have a $40.00 target price on the stock, down from their previous target price of $47.00. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) rose 13.86% to $ 27.52 yesterday on volume of 4,698,207 shares. The intra-day range of the stock was $ 23.22 – 28.12. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has a market capitalization of $ 2.84 billion.
Radnet (NASDAQ:RDNT) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.03) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.06) by $0.03. RadNet Inc. (NASDAQ:RDNT)’s stock on May 9, 2014 reported a increase 21.80% to the closing price of $ 6.48. Its fifty two weeks range is $ 1.50 – 6.74. The total market capitalization recorded $ 268.76 million. The overall volume in the last trading session was 4,588,531 shares. In its share capital, RadNet Inc. (NASDAQ:RDNT) has 41.47 million outstanding shares.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) financial overhang removed, says JMP Securities, after a large block of Avanir’s stock was traded yesterday, JMP Securities thinks the trade represented full utilization of the company’s updated ATM facility. The firm believes the deal bolstered the company’s balance sheet by $500M, addressing a key bear concern. It reiterates an Outperform rating on the stock. On Friday, shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) advanced 6.10% to close the day at $ 4.87. Company return on investment (ROI) is -149.40% and its monthly performance is recorded as 25.84%. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) quarterly revenue growth is 35.65%.